Tagged with

Belgium Eli Lilly Belgium’s Frederic Clais discusses the potential impact of upcoming reform of the country’s access and reimbursement system, the country’s enduring relevance to the company as home to its European Clinical Trial Services (ELECTS) division, and his aim to reach 200,000 patients in Belgium with Lilly treatments before the…

Africa The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one here and part two here). Here, Hwenda examines the persistent challenge of HIV/AIDS…

Global In 2023, we face a new digital relations landscape where a customer and a brand more and more rely on personal data exchange and unique communication channels. In this new reality, marketing means are shifting towards direct communication and personalization, and generic campaigns are making way for communications that target…

Belgium Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million patients via its locally available portfolio. 18 months into his role as Country President for BeLux, Federico Mambretti expands on…

Global Takeda’s Mwana Lugogo and Pfizer’s Rady Johnson, the current and former chairs of the IFPMA Ethics & Business Integrity Committee and Chief Ethics & Compliance Officers Roundtable respectively, highlight the IFPMA’s new ‘Ethoscope’ initiative, which aims to promote ethics and business integrity throughout the industry to sustain and develop trust.…

Belgium One year into his first country management assignment at Takeda Belgium, Michael Nesrallah reflects on his initial impressions of the Belgian pharma market as well as its similarities and differences with that of his native US. Belgium plays host to Takeda’s third-largest manufacturing site globally – a carbon neutral facility…

Greece EY Greece’s George Mitropoulos outlines some of the key challenges and opportunities for both local manufacturers and multinational innovators in Greece, how EY is uniquely positioned to assist them, and the fundamentals that give him cause for optimism for both the Greek economy and its healthcare sector.   We believe…

Europe Alexander Natz of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) casts his eye over the potential effects of the upcoming EU Pharmaceutical Legislation for small- and medium-sized enterprises in Europe. Natz feels that Europe is at a crossroads in terms of its positioning as a driver of innovation and calls…

Belgium After a 25-year-long career at Roche, spent at local affiliates in Switzerland, Germany, and the Netherlands, as well as in global positions in Switzerland and the US, Marie-José Borst took on the role of GM at the firm’s BeLux affiliate. Having spent a year on the job, she explains some…

APAC The latest pharma and healthcare news from Southeast Asia, including the partnership between KPJ Healthcare and Samsung; Specialised Therapeutics’ immuno-oncology therapy; Singapore biotech CytoMed Therapeutics’ IPO, the Malaysian approval of Astrazeneca’s Evusheld and CAR T-cell immunotherapy innovation in Thailand.   Singapore-Sweden research reveals promising stem cell approach for restoring vision…

Belgium With over 140 operating biotech companies representing almost a quarter of Europe’s biotech market and a strong network of universities and research institutes, Belgium boasts a solid biotech ecosystem that continues to thrive despite recent downturns in biotech financing. Beyond more well-known players like Argenx, acquired by Sanofi, and Galapagos,…

USA With a total R&D spend of USD 2.66 billion in 2022 and a pipeline that features cutting-edge technologies such as mRNA, cell therapy and gene editing, Vertex Pharmaceuticals is looking to deliver “serial innovation” by investing most of its resources in research. And while some other biopharma companies depend on…